Department of Medicine, Queen's University, Kingston, ON, K7L 3N6, Canada.
Allergy Research Unit, Kingston Health Sciences Center - KGH Site, Kingston, on, K7L 2V7, Canada.
Immunotherapy. 2021 Oct;13(15):1283-1291. doi: 10.2217/imt-2021-0133. Epub 2021 Sep 24.
Allergic diseases are type 2 inflammatory reactions with an increasing worldwide prevalence, making the search for new therapeutic options pertinent. Allergen immunotherapy is the only disease-modifying approach for allergic rhinitis, though it can result in systemic reactions. Recently, peptide immunotherapy (PIT), involving T-cell epitope peptides that bind to major histocompatibility complexes, have been developed. It is speculated that they can induce T helper cell type 2 anergy, Treg cell upregulation or immune deviation. Promising results in cat dander, honeybee venom, Japanese cedar pollen, grass pollens, ragweed and house dust mite clinical trials have shown safety, efficacy and tolerability to PIT. Hence, PIT may hold the potential to change the treatment algorithm for allergic rhinitis.
变应性疾病是 2 型炎症反应，其全球患病率正在不断增加，因此寻找新的治疗方法具有重要意义。变应原免疫疗法是治疗过敏性鼻炎的唯一方法，但它可能导致全身性反应。最近，开发了涉及与主要组织相容性复合物结合的 T 细胞表位肽的肽免疫疗法 (PIT)。据推测，它们可以诱导辅助性 T 细胞 2 型失能、Treg 细胞上调或免疫偏离。在猫皮屑、蜂毒、日本雪松花粉、草花粉、豚草和屋尘螨的临床试验中取得了有希望的结果，表明 PIT 具有安全性、有效性和耐受性。因此，PIT 可能有潜力改变过敏性鼻炎的治疗方案。
